1. Chung W, Hung S, Hong H, Hsih M, Yang L, Ho H, Wu J, Chen Y. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
2. Hung S, Chung W, Liou L, Chu C, Lin M, Huang H, Lin Y, Lan J, Yang L, Hong H, Chen M, Lai P, Wu M, Chu C, Wang K, Chen C, Fann C, Wu J, Chen Y. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-4139.
3. Nelson M, Bacanu S-A, Mosteller M, Li L, Bowman C, Roses AD, Lai E, Ehm M. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 2008:Epub ahead of print.
4. Mallal S, Phillips E, Carosi G, Molina J, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid J, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-579.
5. Donaldson P, Bhatnagar P, Graham J, Henderson J, Leathart J, Pirmohamed M, Bernal W, Aithal G, Day C, Daly AK. Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor. hepatology 2008;48:396A-397A.
6. Hoskins J, Goldberg R, Qu P, Ibrahim J, McLeod H. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290-1295.
7. Côté J, Kirzin S, Kramar A, Mosnier J, Diebold M, Soubeyran I, Thirouard A, Selves J, Laurent-Puig P, Ychou M. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. J Clin Oncol 2007;13:3269-3275.
8. Martin A, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen F, Mallal S. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005;19:97-99.
9. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008;359:789-799.
10. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, Corso N, Casula B, La Nasa G, Contu L, Manconi P. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006;20:1624-1626.
11. Quteineh L, Verstuyft C, Descot C, Dubert L, Robert A, Jaillon P, Becquemont L. Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose. Thromb Haemost 2005;94:690-1.
12. Lucena M, Andrade R, Martínez C, Ulzurrun E, García-Martín E, Borraz Y, Fernández M, Romero-Gomez M, Castiella A, Planas R, Costa J, Anzola S, Agúndez J. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2009;48:588-596.
13. Daly A, Aithal G, Leathart J, Swainsbury R, Dang T, Day C. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. gastroenterology 2007;132:272-81.
14. Huang YS, Chern H, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35:883-889.
15. Possuelo L, Castelan J, de Brito T, Ribeiro A, Cafrune P, Picon P, Santos A, Teixeira R, Gregianini T, Hutz M, Rossetti M, Zaha A. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008;64:673-681.
16. Kindmark A, Jawaid A, Harbron C, Barratt B, Bengtsson O, Andersson T, Carlsson S, Cederbrant K, Gibson N, Armstrong M, Lagerström-Fermér M, Dellsén A, Brown E, Thornton M, Dukes C, Jenkins S, Firth M, Harrod G, Pinel T, Billing-Clason S, Cardon L, March R. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8:186-195.
17. Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C, Jaillon P. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000;67:432-7.